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Abstract
Trypanosoma cruzi is the causal agent of Chagas disease that affects 6–7 million 
people around the world, principally in Latin America. This disease is character-
ized for the presence of an acute phase in which the host immune response plays 
a central role in the elimination of the parasite. If the parasite is not efficiently 
eliminated, patients can remain asymptomatic or develop a chronic infection. One 
of the cells that are primarily infected with this intracellular parasite is macrophages 
(Mϕ). Mϕ present a wide array of activation states with classically activated mac-
rophages in one pole (CAMϕ) and alternatively activated macrophages (AAMϕ) 
in the other. One of the most important differences between these two activation 
states is the presence of the inducible nitric oxide synthase (iNOS or NOS2) in 
CAMϕ and arginase 1 (Arg-1) in AAMϕ; both enzymes share the same substrate, 
l-arginine, and are reciprocally regulated by the action of Th1 cytokines in the case 
of NOS2 and Th2 cytokines in the case of Arg-1. The activation of CAMϕ permits 
the production of nitric oxide (NO), highly trypanotoxic, while the activation 
of AAMϕ allows the synthesis of polyamines, necessary for parasite duplication. 
l-arginine is a very important metabolite situated in the center between the elimi-
nation and perpetuation of T. cruzi.
Keywords: arginase-1, l-arginine, inducible nitric oxide synthase,  
macrophages, trypanosoma cruzi
1. Introduction
Trypanosoma cruzi is the causal agent of Chagas disease that affects 6–7 million 
people around the world, mainly in Latin America [1], although in the last years it 
has also become a potential public health problem in developed countries due to the 
constant migrations with cases reported in the USA, Canada, Europe, Japan, and 
Australia [2].
This intracellular obligate parasite enters the human host in the form of meta-
cyclic promastigotes that are released from the triatomine feces during the blood 
meal, through damaged skin or mucosae. Alternatively, infection can occur through 
other routes such as oral, congenital, blood transfusions, or organ transplants. 
After entering the host, trypomastigotes are phagocytized mainly by macrophages, 
where they transform to amastigotes, the intracellular form that has the ability to 
replicate. In order to evade the host immune response and ensure its persistence 
inside macrophages, Trypanosoma has developed multiple strategies. One of these 
has as a target l-arginine metabolism. Macrophages can eliminate amastigotes or 
permit their survival depending on the balance of two inducible enzymes nitric 
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oxide synthase (iNOS or NOS2) and arginase-1 (Arg-1) that share the same sub-
strate: l-arginine. During the activation of macrophages in the context known as 
classical activation, l-arginine is metabolized by iNOS giving rise to the production 
of nitric oxide (NO), one important trypanotoxic agent that permits these cells to 
destroy the parasite. On the other hand, during the activation of macrophages in the 
context known as alternative activation, l-arginine is metabolized by Arg-1 giving 
rise to the production of polyamines that favor multiplication and persistence of 
Trypanosoma in these cells. Thus, l-arginine is situated as a frontier between the 
elimination and survival of Trypanosoma in macrophages, and its metabolism is a 
determinant factor for the evolution of the disease.
2. Phases of the infection with Trypanosoma cruzi
The infection with T. cruzi presents an acute phase that is auto-limiting and can 
go unnoticed in many infected individuals. During this phase, parasites actively 
duplicate in different cells and tissues such as macrophages; muscular cells of 
smooth, striated, and cardiac muscles; adipocytes; and cells of the central nervous 
system [3]. While some patients succumb during the acute phase of the disease, the 
development of an adaptive immune generally permits the control of infection with 
T. cruzi. If the parasite is not completely eradicated, individuals remain infected 
for life, and a dynamic equilibrium is established with the parasite that results in 
different clinical outcomes. In this way, while many individuals chronically infected 
remain in an asymptomatic intermediate phase, a significant proportion (30–35%) 
of patients develop cardiac or digestive manifestations that can drive them to 
congestive cardiac failure, arrhythmias, and eventually death or develop colon or 
esophageal megasyndromes. All of these are irreversible pathologic changes that 
occur even though the presence of the parasite is scarce. One experimental model 
that recapitulates chagasic myocarditis is present in infected mice for long periods 
with different T. cruzi strains that develop chronic lesion in the myocardium [4, 5].
3. Generalities of l-arginine
ʟ-arginine is one of the most versatile amino acids at the metabolic level. Besides 
serving as a precursor for protein synthesis, it is also a precursor of multiple 
compounds of great biologic importance such as urea, nitric oxide, polyamines, 
l-proline, glutamate, creatinine, and agmatine (Figure 1) [6, 7].
In adult mammals, ʟ-arginine is a nonessential amino acid; nevertheless, during 
childhood and certain physiologic or pathologic conditions (e.g., pregnancy, sepsis, 
trauma, catabolic stress, intestinal or renal damage), it is considered as a semi-
essential amino acid or conditioned nonessential, due to the fact that its consumption 
exceeds the capacity of being synthesized by the organism and has to be supplied 
exogenously [8–10]. In mammals, the provision of l-arginine depends on its procure-
ment through the protein diet, endogenous synthesis (de novo synthesis), and its 
release during the process of protein replacement (Figure 1) [6]. Approximately 40% 
of the l-arginine that is obtained from the protein diet is catabolized in the intestine 
before entering the circulation [11]. In the absence of the contribution by the protein 
diet, approximately 80% of the ʟ-arginine that enters the circulation derives from 
the protein replacement, and the remaining percentage is obtained through the 
novo synthesis [11]. l-arginine metabolism occurs basically in the liver and kidney; 
nevertheless, other tissues and cells also possess the required enzymes to metabolize 
it, including some cells of the immune response [12]. Regarding last point, it is 
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interesting to note that a complete urea cycle has been described in macrophages 
[13]. Although only two enzymes directly involved in l-arginine synthesis have been 
identified (arginine succinate synthetase and arginine succinate lyase that are the 
third and fourth enzymes of the urea cycle), four enzymes utilize this amino acid 
as substrate: arginine decarboxylase, arginine/glycine aminotransferase, different 
isoforms of arginase (Arg), and the different isoforms of the nitric oxide synthases 
(NOS), the last two being the most studied and characterized [12]. In mammals two 
arginase isoforms exist, Arg-1 and Arg-2, that catalyze the same reaction but differ 
in cellular expression and subcellular localization. Arg-1 is cytosolic and is highly 
expressed in the liver and some cells of the immune response. Compared to Arg-1, 
Arg-2 is mitochondrial and is expressed in a great variety of peripheral tissues, 
mainly in the kidney, prostate, small intestine, and mammary glands during lacta-
tion [14]. Regarding NOS, this enzyme is present in three isoforms: neuronal NOS 
(nNOS or NOS1), inducible nitric oxide synthase (iNOS or NOS2), and endothelial 
NOS (eNOS or NOS3). NOS 1 is expressed in specific neurons of the central nervous 
system (CNS), and NOS3 is mostly expressed in endothelial cells [15]. NOS 2 is not 
usually expressed in cells, but its expression can be induced by bacterial lipopolysac-
charide, cytokines, and other agents. Although primarily identified in macrophages, 
the expression of this enzyme can be stimulated in almost any cell or tissue, provided 
that the appropriate inducing agents are present [16].
4.  l-arginine metabolism in the immune response: special emphasis in 
macrophages
In the immune response, ʟ-arginine metabolism through NOS2 and Arg-1 has a 
pivotal role in the regulation of the effector capabilities of macrophages, dendritic 
cells, and neutrophils [17–20] during infectious processes caused by a great variety 
of microorganisms: different species of Mycobacterium, Leishmania, Trypanosoma, 
Schistosoma, and Salmonella, among others [21, 22].
l-arginine metabolism in the immune response acquired great relevance with 
the discovery that murine macrophages express both NOS2 and Arg-1 and that their 
expression is reciprocally regulated by the action of Th1/proinflammatory cyto-
kines (e.g., IFN-γ and TNF-α) and Th2/anti-inflammatory (e.g., IL-4, IL-10, and 
IL-13) that determine the activation state of macrophages [19, 23–27].  
Figure 1. 
Sources of L-arginine in mammals and its metabolic products.
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Th1 cytokines activate macrophages in a classical way (CAMФ) and induce the 
expression and function of NOS2, while Th2 cytokines activate macrophages in an 
alternative way (AAMФ) and induce the expression and function of Arg-1.
NOS2 or iNOS is an oxide-reductase responsible for the synthesis of l-citrulline 
and nitric oxide (NO•) from ʟ-arginine in the presence of NADPH and oxygen. 
This reaction occurs through two successive reactions: the monooxygenation of 
ʟ-arginine that drives to the production of the intermediary Nω-OH- l-arginine 
(NOHA) and the subsequent hydrolysis of this last compound, thus producing 
ʟ-citrulline and NO• (Figure 2). NOS2 generates both NO• and superoxide (O2−) 
that together react to form the radical peroxynitrite (ONOO−) [28]. This last 
compound has been identified as a reactive species derived both from oxygen and 
nitrogen (RONS) that constitutes the principal cytostatic or cytotoxic mechanism 
of CAMФ to fight the infections generated by virus, bacteria, fungi, and protozoan 
parasites [20, 23, 26, 29].
5. Immune response to Trypanosoma cruzi
Inside the mammalian host, macrophages represent an important site for the 
duplication of T. cruzi. One of the most important mechanisms in the protective 
immunity against T. cruzi is the activation of macrophages in order to achieve the 
elimination of parasites (Figure 3). CAMϕ are able eliminate T. cruzi thanks to 
Figure 2. 
l-arginine metabolism through iNOS and Arg-1. iNOS, inducible nitric oxide synthase; Arg-1, arginase 1; 
NOHA, Nω–OH-l-arginine; OAT, ornithine-aminotransferase; ODC, ornithine-decarboxylase; NO•, nitric 
oxide; O2
−, superoxide, RNOS, oxygen and nitrogen reactive species; ONOO-, peroxynitrite.
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NOS2 and RONS that kill intracellular parasites by the modification of structural 
properties of T. cruzi molecules. On the other hand, the different forms of AAMϕ 
present high levels of mannose receptor (MR) and an overregulation of Arginase 
1 [30]. Arg-1 hydrolyzes ʟ-arginine in urea and ʟ-ornithine; the latter is the 
principal intracellular source for the synthesis of polyamines and trypanothione. 
Polyamines are small cationic molecules required for cellular proliferation and 
macrophage homeostatic processes, besides being vital for the intracellular growth 
of Trypanosoma [19, 31]. Both inducible enzymes share ʟ-arginine as substrate, 
and the expression and function of both enzymes are reciprocally regulated by the 
action of Th1 and Th2 cytokines. Thus, ʟ-arginine is situated as a frontier between 
the elimination and survival of Trypanosoma in host cells, and its metabolism is a 
determinant factor in the evolution of the disease.
In response to the defense mechanisms of the host, parasites have developed 
several strategies in order to escape host immune response and take advantage of 
some host’s molecules. In this way, parasites must reduce the production of toxic 
molecules, including nitric oxide and its derivatives, that are synthesized by the 
immune system, in particular by macrophages [32–34]. In addition, internalized 
parasites of different T. cruzi strains are able to escape from the parasitophorous 
vacuole of resident macrophages [35], a strategy that utilizes a variety of molecules 
with antioxidant properties [36, 37]. Nevertheless, as the infection progresses, the 
evasion strategies displayed by T. cruzi are widely surpassed by the development of 
a humoral specific immune response and the activation of macrophages by IFN-𝛾 
and other cytokines. As has been previously mentioned, the infection with T. cruzi 
can have an acute or a chronic phase. One of the possible causes of the passage 
from one phase to another is the fact that the effector immune response against the 
parasite is insufficient or inappropriate due to a deficient activation of the specific 
immune response or an excessive regulation of this response.
6. Role of Arg-1 in the infection with Trypanosoma
The induction of Arg-1 in macrophages promotes the infection of parasites of 
the genus Trypanosoma by providing nutrients derived from polyamines, since 
Trypanosoma parasites cannot generate their own source of ornithine through the 
activity of a functional arginase [38, 39]. The increase in arginase activity coun-
teracts the host’s immune response and favors parasite growth. It has been shown 
that in African trypanosomiasis caused by Trypanosoma gambiense, there is an 
increase in the serum level of Arg-1 that returns to basal values after the treatment 
Figure 3. 
l-arginine metabolism in macrophages during T. cruzi infection. In classically activated macrophages 
(CAMФ), inducible nitric oxide synthase (iNOS) expression and function are induced. l-arginine 
metabolism through this enzyme entails the production of nitric oxide that possesses great trypanocidal 
capacity. In alternatively activated macrophages (AAMФ), arginase 1 (Arg-1) expression and function are 
induced. l-arginine metabolism through this enzyme entails the production of polyamines that favor T. cruzi 
multiplication inside macrophages.
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[40]. Similarly, in experimental murine trypanosomiasis caused by Trypanosoma 
brucei, macrophage Arg-1 activity represents a disease susceptibility marker [41]. 
In T. brucei Arg-1 activity is induced by excretion/secretion factors, particularly 
TbKHC1, kinesin H chain, and has been identified as an inductor factor of Arg-1 
[38]. Other studies have demonstrated that the addition of an Arg-1 inhibitor 
reduces parasite growth, which is restored with l-ornithine supplementation. The 
essential requirement of l-ornithine is related with the absence of a functional 
arginase in Trypanosoma [39], which results in a dependence toward host’s arginase 
for the synthesis of polyamines and trypanothione, which are essential for parasite 
survival, growth, and differentiation [42]. The difluoromethylornithine, structural 
analog of l-ornithine, has been used alone or in combination with nifurtimox as an 
effective drug against African trypanosomiasis [43]. Nevertheless, its administration 
is difficult and requires large amounts of i.v. injected fluids, which limits its use in 
remote areas. Thus, it is of utmost importance to find easier ways to select polyamine 
synthesis as a target against Trypanosoma. Alternatively, inhibitors of the route that 
conducts to arginase activity might reduce parasite loads in infected animals.
7. Conclusion
Trypanosoma cruzi is the causal agent of Chagas disease that affects 6–8 million 
people primarily in Latin America. It is an intracellular parasite that infects a variety 
of cells, among which macrophages are a very important target and thus transcen-
dental for the immune response against the parasite. Macrophages can traverse 
through a gradient of stages of activation with classically activated macrophages in 
one end and alternatively activated macrophages in the other. These two phases of 
activation are characterized by the expression of two enzymes that are reciprocally 
regulated and share the same substrate: l-arginine. Classically activated macrophages 
express iNOS of NOS2 that is induced by Th1 cytokines and catalyze the conversion 
of l-arginine to l-citrulline and NO. Contrarily, alternatively activated macrophages 
express Arg-1 that is induced by Th2 cytokines. Thus, l-arginine metabolism is in the 
center of Trypanosoma elimination of survival. The better knowledge of this route 
during the different stages of Trypanosoma infection is of great importance for the 
better comprehension of disease progression and design of drugs.
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